Please assess the completion status of the following clinical trial:

Trial Title: Effects of Short Term, High Dose Atorvastatin Therapy on Periprocedural Myonecrosis and Platelet Inhibition After Percutaneous Coronary Intervention (PCI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients undergoing revascularization for significant coronary artery disease~* age range 21-85 years~Exclusion Criteria:~* non-STEMI, STEMI~* cancer~* renal failure with creatinine\>3.0mg/dl~* liver cirrhosis~* lymphoproliferative disorder~* pregnancy~* thrombocytopenia\<150'000~* coagulopathy (INR\>1.5)~* abnormal liver function tests~* illicit drug use~* history of statin intolerance~* history of rhabdomyolysis~* planned use of Glycoprotein IIb/IIIa inhibitors during PCI~* current therapy with atorvastatin, pravastatin, lovastatin, fluvastatin, or rosuvastatin

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- No atorvastatin (Type: NO_INTERVENTION): Patients do not receive Atorvastatin prior to PCI in cath lab
- atorvastatin (Type: EXPERIMENTAL): Atorvastatin 80mg po given prior to PCI in cath lab

Based on this trial design, predict the completion outcome and termination type (if applicable).